Morgan Stanley’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.37K | Sell |
3,922
-1,000
| -20% | -$752 | ﹤0.01% | 7300 |
|
|
2025
Q4 | $3.79K | Sell |
4,922
-3,337
| -40% | -$3.01K | ﹤0.01% | 7116 |
|
|
2025
Q3 | $8.34K | Buy |
8,259
+825
| +11% | +$970 | ﹤0.01% | 6950 |
|
|
2025
Q2 | $9.89K | Sell |
7,434
-9,881
| -57% | -$13.4K | ﹤0.01% | 6862 |
|
|
2025
Q1 | $20.6K | Sell |
17,315
-579
| -3% | -$824 | ﹤0.01% | 6566 |
|
|
2024
Q4 | $29.2K | Sell |
17,894
-9,538
| -35% | -$25.2K | ﹤0.01% | 6459 |
|
|
2024
Q3 | $105K | Sell |
27,432
-46,556
| -63% | -$155K | ﹤0.01% | 5989 |
|
|
2024
Q2 | $217K | Buy |
73,988
+1,217
| +2% | +$3.89K | ﹤0.01% | 5633 |
|
|
2024
Q1 | $288K | Sell |
72,771
-97,521
| -57% | -$502K | ﹤0.01% | 5582 |
|
|
2023
Q4 | $846K | Buy |
170,292
+101,474
| +147% | +$504K | ﹤0.01% | 5378 |
|
|
2023
Q3 | $348K | Buy |
68,818
+1,547
| +2% | +$8.47K | ﹤0.01% | 5325 |
|
|
2023
Q2 | $338K | Sell |
67,271
-36,589
| -35% | -$240K | ﹤0.01% | 5407 |
|
|
2023
Q1 | $639K | Sell |
103,860
-119,875
| -54% | -$981K | ﹤0.01% | 5116 |
|
|
2022
Q4 | $2.95M | Buy |
223,735
+208,315
| +1,351% | +$1.47M | ﹤0.01% | 4182 |
|
|
2022
Q3 | $46K | Buy |
15,420
+1,049
| +7% | +$4.45K | ﹤0.01% | 6448 |
|
|
2022
Q2 | $52K | Sell |
14,371
-2,254
| -14% | -$10.7K | ﹤0.01% | 6592 |
|
|
2022
Q1 | $103K | Sell |
16,625
-3,825
| -19% | -$23.8K | ﹤0.01% | 6289 |
|
|
2021
Q4 | $166K | Buy |
20,450
+14,724
| +257% | +$158K | ﹤0.01% | 6162 |
|
|
2021
Q3 | $85K | Sell |
5,726
-59,977
| -91% | -$748K | ﹤0.01% | 6462 |
|
|
2021
Q2 | $825K | Buy |
65,703
+62,913
| +2,255% | +$491K | ﹤0.01% | 5199 |
|
|
2021
Q1 | $13K | Buy |
2,790
+1,090
| +64% | +$4.39K | ﹤0.01% | 6868 |
|
|
2020
Q4 | $4K | Sell |
1,700
-4,400
| -72% | -$9.64K | ﹤0.01% | 6808 |
|
|
2020
Q3 | $14K | Buy |
+6,100
| New | +$17.1K | ﹤0.01% | 6168 |
|
|
2020
Q1 | – | Sell |
-27
| Closed | – | – | 6665 |
|
|
2019
Q4 | $0 | Sell |
27
-25
| -48% | -$71 | ﹤0.01% | 6730 |
|
|
2019
Q3 | $0 | Hold |
52
| – | – | ﹤0.01% | 6718 |
|
|
2019
Q2 | $0 | Sell |
52
-3
| -5% | -$20 | ﹤0.01% | 6711 |
|
|
2019
Q1 | $0 | Sell |
55
-1
| -2% | -$8 | ﹤0.01% | 6672 |
|
|
2018
Q4 | $0 | Sell |
56
-59
| -51% | -$781 | ﹤0.01% | 6689 |
|
|
2018
Q3 | $2K | Sell |
115
-2,758
| -96% | -$49.6K | ﹤0.01% | 6580 |
|
|
2018
Q2 | $58K | Buy |
2,873
+600
| +26% | +$12.5K | ﹤0.01% | 5884 |
|
|
2018
Q1 | $54K | Sell |
2,273
-159
| -7% | -$42.8K | ﹤0.01% | 5868 |
|
|
2017
Q4 | $456K | Buy |
2,432
+284
| +13% | +$57.1K | ﹤0.01% | 5025 |
|
|
2017
Q3 | $460K | Buy |
2,148
+763
| +55% | +$158K | ﹤0.01% | 4927 |
|
|
2017
Q2 | $284K | Buy |
1,385
+293
| +27% | +$57.7K | ﹤0.01% | 5142 |
|
|
2017
Q1 | $199K | Sell |
1,092
-1,317
| -55% | -$261K | ﹤0.01% | 5328 |
|
|
2016
Q4 | $602K | Buy |
2,409
+1,282
| +114% | +$291K | ﹤0.01% | 4809 |
|
|
2016
Q3 | $235K | Buy |
1,127
+101
| +10% | +$20K | ﹤0.01% | 4943 |
|
|
2016
Q2 | $208K | Buy |
1,026
+67
| +7% | +$11.8K | ﹤0.01% | 4918 |
|
|
2016
Q1 | $175K | Buy |
959
+777
| +427% | +$139K | ﹤0.01% | 5054 |
|
|
2015
Q4 | $46K | Buy |
+182
| New | +$58.7K | ﹤0.01% | 5750 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
Morgan Stanley's PDSB Position: Q1 2026 in Review
Morgan Stanley reduced its PDS Biotechnology (PDSB) stake by 20% in Q1 2026, selling an estimated $752 and leaving 3,922 shares worth $2.37K. The position accounts for ﹤0.01% of the portfolio, ranked #7300.
Morgan Stanley first reported a position in PDSB in Q4 2015 and has held it in 40 quarters since. The position peaked at $2.95M in Q4 2022. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- Morgan Stanley held 3,922 shares of PDS Biotechnology worth $2.37K as of Q1 2026.
- Morgan Stanley sold 1,000 PDS Biotechnology shares in Q1 2026, an estimated $752.
- PDS Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7300 holding.
- Morgan Stanley first reported a position in PDS Biotechnology in Q4 2015 and has held it in 40 quarters since.
- Morgan Stanley's PDS Biotechnology position peaked at $2.95M in Q4 2022.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.